Professor of Oncology, Professor of Urology, Johns Hopkins University School of Medicine; AEGON Professor of Prostate Cancer Research, Co-Director, Prostate Cancer/GU Oncology Program, Co-Director, Chemical Therapeutics
Oncology
Dr. Michael A. Carducci, MD
|
|
Give Review
Michael Carducci practices Oncology. He attended Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63/85 in Research/PrimaryCare. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Michael Carducci is a published doctor. He has 100 papers published. The most current publication "Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate c..." Michael Carducci accepts Medicare payments and is registered with Medicare.gov.
Publications
- Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic Breast and prostate c...
- Comorbid condition care quality in Cancer survivors: role of primary care and specialty providers and care coordination.
- Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate Cancer: results from a pilot clinical study.
- An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced Cancer.
- A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: E...
- Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs.
- Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate Cancer treated on Cancer and Leukemia Group ...
- Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate Cancer.
- Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
- Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline.
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase 3 metastatic castration resistant prostate Cancer trial.
- Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate Cancer (mCRPC).
- Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate Cancer.
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate Cancer.
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid Tumors.
- It's who you know: patient-sharing, quality, and costs of Cancer survivorship care.
- The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer.
- Bone-targeting agents in prostate Cancer.
- An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial Cancer.
- Management of patients with biochemical recurrence after local therapy for prostate Cancer.
- Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant...
- Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate Cancer (mCRPC) tre...
- The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate Cancer.
- A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate Cancer before radical prostatectomy.
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate Cancer (SWOG S0421): a randomised phase 3 trial.
- Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell Carcinomas.
- Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate Cancer.
- Analysis of the genomic response of human prostate Cancer cells to histone deacetylase inhibitors.
- Targeting prostate Cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
- Screening assay for blood vessel maturation inhibitors.
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate Cancer: Resu...
- Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure.
- Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal Cancer.
- Feasibility and value of PatientViewpoint: a web System for patient-reported outcomes assessment in clinical practice.
- Quality of care for comorbid conditions during the transition to survivorship: differences between Cancer survivors and nonCancer controls.
- A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate Cancer.
- Tales of How Great Drugs Were Brought Down by a Flawed Rationale--Letter.
- Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate C...
- A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate Cancer.
- Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metast...
- Mechanism of growth inhibition of prostate Cancer xenografts by valproic Acid.
- A phase I/IIA study of AGS-PSCA for castration-resistant prostate Cancer.
- Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for Cancer therapy.
- An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate Cancer patients receiving adjuvant docetaxel after prostatectomy.
- Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell Carcinomas.
- Targeting angiogenesis for the treatment of prostate Cancer.
- Use of androgen deprivation therapy in prostate Cancer: indications and prevalence.
- Progression of Prostate Carcinogenesis and Dietary Methyl Donors: TempOral Dependence.
- Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate ca...
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib f...
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
- Kidney Cancer.
- Role of immunotherapy for renal cell Cancer in 2011.
- Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas.
- Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate Cancer treated with nonhormonal agents: Combined analysis of 4 phase II tri...
- A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve...
- The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
- Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate Cancer: Clinical factors associated with PSA response and disease p...
- Angiotensin System inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination.
- Preventive care in prostate Cancer patients: following diagnosis and for five-year survivors.
- New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety.
- Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate Cancer.
- The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate Cancer treated with intermittent androgen...
- Can patient-reported outcome measures identify Cancer patients' most bothersome issues?
- Disulfiram is a DNA demethylating agent and inhibits prostate Cancer cell growth.
- NCCN Task Force report: optimizing treatment of advanced renal cell Carcinoma with molecular targeted therapy.
- Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression.
- How does initial treatment choice affect short-term and long-term costs for clinically localized prostate Cancer?
- Future directions in castrate-resistant prostate Cancer therapy.
- Castration-dependent pharmacokinetics of docetaxel in patients with prostate Cancer.
- Recent time trends in the epidemiology of stage IV prostate Cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program.
- A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate Cancer.
- Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate Cancer is mediated through the E2F1 transcription factor.
- Phase I trial with a combination of docetaxel and ¹âµ³Sm-lexidronam in patients with castration-resistant metastatic prostate Cancer.
- Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate Cancer: evaluation of drug-specific biomarkers.
- A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid Tumors.
- NCCN clinical practice guidelines in oncology: testicular Cancer.
- NCCN clinical practice guidelines in oncology: kidney Cancer.
- Copy number analysis indicates monoclonal origin of lethal metastatic prostate Cancer.
- Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate Cancer cells in vitro and in vivo.
- Fenugreek: a naturally occurring edible spice as an antiCancer agent.
- Department of Defense prostate Cancer clinical trials consortium: a new instrument for prostate Cancer clinical research.
- Effect of DNA methylation on identification of aggressive prostate Cancer.
- A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate Cancer.
- A multiple-loop, double-cube microarray design applied to prostate Cancer cell lines with variable sensitivity to histone deacetylase inhibitors.
- Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate Cancer.
- Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
- Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid Tumors.
- Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
- Phase II open-label study of oral piritrexim in patients with advanced Carcinoma of the urothelium who have experienced failure with standard chemotherapy.
- The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate Cancer developed following radical prostatectomy.
- Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate Cancer.
- Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate Cancer demonstrate the inadequacy of PSA response as a primary endpo...
- Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate Cancer cells in vitro and in vivo.
- Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate Cancer.
- Phase II study of imatinib mesylate in patients with prostate Cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiothe...
- Prostate Cancer: a practical approach to current management of recurrent disease.
- The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.
Schools
Wayne State University
University Colo Health Scis Center
Johns Hopkins Onco Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
University of Colorado -
Wayne State University School of Medicine
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1952369977 | |
| NPPES Provider LastName | CARDUCCI | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 180.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952369977 |
| Last Name Of The Provider | CARDUCCI |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Katherine H. Tkaczuk, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart A. Grossman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ting Bao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Curt I. Civin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yixing Jiang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vered Stearns, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rosalyn A. Juergens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dung T. Le, MD |